{"id":19870,"date":"2024-12-26T06:34:08","date_gmt":"2024-12-26T05:34:08","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2024\/12\/26\/targeting-immune-evasion-in-hepatocellular-carcinoma-initiating-cells-rafael-sirera\/"},"modified":"2024-12-26T06:34:08","modified_gmt":"2024-12-26T05:34:08","slug":"targeting-immune-evasion-in-hepatocellular-carcinoma-initiating-cells-rafael-sirera","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2024\/12\/26\/targeting-immune-evasion-in-hepatocellular-carcinoma-initiating-cells-rafael-sirera\/","title":{"rendered":"Targeting immune evasion in hepatocellular carcinoma-initiating cells. Rafael Sirera"},"content":{"rendered":"<div>\n<p>Trends Immunol. 2024 Dec 24:S1471-4906(24)00304-1. doi: 10.1016\/j.it.2024.12.002. Online ahead of print.<\/p>\n<p>ABSTRACT<\/p>\n<p>Tumor-initiating cells (TICs) are particularly efficient at evading detection and elimination by the human immune system. Recent data from Yang and collaborators demonstrate that &#8211; at least in preclinical hepatocellular carcinoma models &#8211; the immunological privilege of CD49f+ TICs can be limited by targeting CD155, resulting in restored sensitivity to immune checkpoint inhibitors.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39721855\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=100966032&amp;ff=20241226003407&amp;v=2.18.0.post9+e462414\">39721855<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.it.2024.12.002\">10.1016\/j.it.2024.12.002<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Trends Immunol. 2024 Dec 24:S1471-4906(24)00304-1. doi: 10.1016\/j.it.2024.12.002. Online ahead of print. ABSTRACT Tumor-initiating cells (TICs) are particularly efficient at evading detection and elimination by the human immune system. Recent data from Yang and collaborators demonstrate that &#8211; at least in preclinical hepatocellular carcinoma models &#8211; the immunological privilege of CD49f+ TICs can be limited by &#8230; <a title=\"Targeting immune evasion in hepatocellular carcinoma-initiating cells. Rafael Sirera\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2024\/12\/26\/targeting-immune-evasion-in-hepatocellular-carcinoma-initiating-cells-rafael-sirera\/\" aria-label=\"Read more about Targeting immune evasion in hepatocellular carcinoma-initiating cells. Rafael Sirera\">Read more<\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,68],"tags":[],"class_list":["post-19870","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-trends-in-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/19870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=19870"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/19870\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=19870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=19870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=19870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}